OS
OSSFF.US Össur hf
- Market cap
- USD 1.92B
- P/E
- 20.6x
- P/B
- 2.03x
- ROE
- 9.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OSSFF.US undervalued?
Graham numberOSSFF.US trades 36.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Össur hf fundamental analysis
No fundamental analysis for Össur hf yet.
Össur hf stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Össur hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, …
Full company profileÖssur hf financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Össur hf annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 521M | 569M | 613M | 686M | 630M | 719M | 719M | 786M | 855M | 964M | 983M |
| Gross Profit | 328M | 355M | 387M | 439M | 391M | 455M | 440M | 486M | 535M | 561M | 599M |
| Operating Income | 72.2M | 74.8M | 78.9M | 98.6M | 22.3M | 97.3M | 64.8M | 89.4M | 113M | 129M | 137M |
| EBITDA | 92.8M | 99.8M | 119M | 144M | 87.0M | 147M | 117M | 146M | 170M | 190M | 202M |
| Net Income | 51.0M | 57.6M | 79.8M | 66.0M | 6.21M | 64.0M | 42.5M | 58.4M | 68.3M | 86.5M | 92.8M |
| EPS | 0.12 | 0.13 | 0.19 | 0.16 | 0.01 | 0.15 | 0.10 | 0.14 | 0.16 | 0.20 | 0.22 |
| Balance Sheet | |||||||||||
| Total Assets | 746M | 793M | 914M | 1.09B | 1.21B | 1.25B | 1.33B | 1.39B | 1.54B | 1.74B | 1.69B |
| Total Liabilities | 279M | 293M | 376M | 522M | 637M | 620M | 690M | 681M | 758M | 849M | 743M |
| Shareholders' Equity | 466M | 500M | 534M | 564M | 573M | 622M | 636M | 702M | 777M | 889M | 941M |
| Cash & Short-term Investments | 35.1M | 37.3M | 55.7M | 58.6M | 102M | 85.2M | 76.6M | 72.7M | 86.2M | 102M | 77.8M |
| Total Debt | 155M | 159M | 235M | 360M | 483M | 448M | 481M | 468M | 500M | 542M | 488M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 66.3M | 73.9M | 69.4M | 95.3M | 92.2M | 101M | 60.8M | 94.3M | 116M | 142M | 111M |
| Capital Expenditure | 24.6M | 19.2M | 30.9M | 31.9M | 24.0M | 26.7M | 25.9M | 42.3M | 39.2M | 22.9M | 19.6M |
| Free Cash Flow | 41.7M | 54.7M | 38.6M | 63.4M | 68.2M | 73.8M | 34.8M | 52.0M | 76.8M | 119M | 91.8M |
| Ratios | |||||||||||
| ROE | 10.9% | 11.5% | 14.9% | 11.7% | 1.1% | 10.3% | 6.7% | 8.3% | 8.8% | 9.7% | 9.9% |
| ROA | 6.8% | 7.3% | 8.7% | 6.1% | 0.5% | 5.1% | 3.2% | 4.2% | 4.4% | 5.0% | 5.5% |
| Net Profit Margin | 9.8% | 10.1% | 13.0% | 9.6% | 1.0% | 8.9% | 5.9% | 7.4% | 8.0% | 9.0% | 9.4% |
| Debt to Equity | 0.33x | 0.32x | 0.44x | 0.64x | 0.84x | 0.72x | 0.76x | 0.67x | 0.64x | 0.61x | 0.52x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Össur hf dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Mar 13, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 9.28M | 0.02 | 149.3% |
| 2019 | USD 9.06M | 0.02 | 13.7% |
| 2018 | USD 9.18M | 0.02 | 11.5% |
| 2017 | USD 7.34M | 0.02 | 12.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Össur hf
- Insiders 11.69%
- Institutions 78.72%
- Public & others 9.59%
- Shares outstanding 425M
- Free float 156M
Össur hf company profile
- Company name
- Össur hf
- Ticker
- OSSFF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,500
- Fiscal year end
- December
- Address
- Grjótháls 5, Reykjavik, Iceland
- Phone
- 354 515 1300
- Website
- emblamedical.com
About Össur hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Össur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
Össur hf management
10- Mr. Sveinn SolvasonPresident & CEO · born 1978
- Mr. Ossur KristinssonFounder · born 1943
- Ms. Gudny Arna SveinsdottirChief Financial Officer · born 1966
- Mr. Lukas MarklinChief Operating Officer · born 1974
- Mr. Klaus SindahlHead of Investor Relations
- Edda H. GeirsdottirVP of Corporate Communications
- Ms. Margret Lara FridriksdottirExecutive Vice President of People, Strategy & Sustainability · born 1978
- Mr. Olafur GylfasonExecutive Vice President of Chronic Solutions · born 1969
- Mr. Christian RobinsonPresident Americas & Global Bracing · born 1982
- Mr. Andre RochaExecutive Vice President of Research & Development · born 1978